Literature DB >> 15755284

Methylation status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia.

Daisuke Hasegawa1, Atsushi Manabe, Takeo Kubota, Hirohide Kawasaki, Imiko Hirose, Yoshitoshi Ohtsuka, Toshihisa Tsuruta, Yasuhiro Ebihara, Yu-ichi Goto, Xiao Yan Zhao, Kazuo Sakashita, Kenichi Koike, Mariko Isomura, Seiji Kojima, Akinori Hoshika, Kohichiro Tsuji, Tatsutoshi Nakahata.   

Abstract

Aberrant DNA methylation is frequently observed in adults with myelodysplastic syndrome (MDS), and is recognized as a critical event in the disease's pathogenesis and progression. This is the first report to investigate the methylation status of p15 and p16, cell cycle regulatory genes, in children with MDS (n = 9) and juvenile myelomonocytic leukaemia (JMML; n = 18) by using a methylation-specific polymerase chain reaction. The frequency of p15 hypermethylation in paediatric MDS was 78% (7/9), which was comparable to that in adult MDS. In contrast, p15 hypermethylation in JMML was a rare event (17%; 3/18). In JMML, clinical and laboratory characteristics including PTPN11 mutations and aberrant colony formation were not different between the three patients with hypermethylated p15 and the others. Aberrant methylation of p16 was not detected in children with either MDS or JMML. Since p15 and p16 genes were unmethylated in two children with JMML, in whom the disease had progressed with an increased number of blasts, a condition referred to as blastic crisis, we infer that the aberrant methylation of these genes is not responsible for the progression of JMML. The results suggest that demethylating agents may be effective in most children with MDS and a few patients with JMML.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15755284     DOI: 10.1111/j.1365-2141.2005.05392.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

1.  Molecular basis of juvenile myelomonocytic leukemia.

Authors:  Andrica C H de Vries; C Michael Zwaan; Marry M van den Heuvel-Eibrink
Journal:  Haematologica       Date:  2010-02       Impact factor: 9.941

2.  RASA4 undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia.

Authors:  Anna R Poetsch; Daniel B Lipka; Tania Witte; Rainer Claus; Peter Nöllke; Manuela Zucknick; Christiane Olk-Batz; Silvia Fluhr; Michael Dworzak; Barbara De Moerloose; Jan Starý; Marco Zecca; Henrik Hasle; Markus Schmugge; Marry M van den Heuvel-Eibrink; Franco Locatelli; Charlotte M Niemeyer; Christian Flotho; Christoph Plass
Journal:  Epigenetics       Date:  2014-07-31       Impact factor: 4.528

Review 3.  Gene mutations do not operate in a vacuum: the increasing importance of epigenetics in juvenile myelomonocytic leukemia.

Authors:  Christian Flotho
Journal:  Epigenetics       Date:  2019-03-08       Impact factor: 4.528

4.  STAT3 signaling pathway is involved in decitabine induced biological phenotype regulation of acute myeloid leukemia cells.

Authors:  Zhichao Zhu; Xuzhang Lu; Lijia Jiang; Xiao Sun; Haijun Zhou; Zhuxia Jia; Xiuwen Zhang; Lingdi Ma
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

5.  Epigenetic silencing of AKAP12 in juvenile myelomonocytic leukemia.

Authors:  Thomas Wilhelm; Daniel B Lipka; Tania Witte; Justyna A Wierzbinska; Silvia Fluhr; Monika Helf; Oliver Mücke; Rainer Claus; Carolin Konermann; Peter Nöllke; Charlotte M Niemeyer; Christian Flotho; Christoph Plass
Journal:  Epigenetics       Date:  2016-02-18       Impact factor: 4.528

6.  The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years' experience of a single center.

Authors:  Junyan Gao; Yixin Hu; Li Gao; Peifang Xiao; Jun Lu; Shaoyan Hu
Journal:  BMC Pediatr       Date:  2022-05-27       Impact factor: 2.567

7.  Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation.

Authors:  Nicolas Waespe; Machiel Van Den Akker; Robert J Klaassen; Lani Lieberman; Meredith S Irwin; Salah S Ali; Mohamed Abdelhaleem; Bozana Zlateska; Mira Liebman; Michaela Cada; Tal Schechter; Yigal Dror
Journal:  Haematologica       Date:  2016-08-18       Impact factor: 9.941

8.  Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease.

Authors:  Marco Tartaglia; Simone Martinelli; Lorenzo Stella; Gianfranco Bocchinfuso; Elisabetta Flex; Viviana Cordeddu; Giuseppe Zampino; Ineke van der Burgt; Antonio Palleschi; Tamara C Petrucci; Mariella Sorcini; Claudia Schoch; Robin Foa; Peter D Emanuel; Bruce D Gelb
Journal:  Am J Hum Genet       Date:  2005-12-07       Impact factor: 11.025

9.  International Consensus Definition of DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia.

Authors:  Maximilian Schönung; Julia Meyer; Hideki Muramatsu; Christian Flotho; Elliot Stieglitz; Daniel B Lipka; Peter Nöllke; Adam B Olshen; Mark Hartmann; Norihiro Murakami; Manabu Wakamatsu; Yusuke Okuno; Christoph Plass; Mignon L Loh; Charlotte M Niemeyer
Journal:  Clin Cancer Res       Date:  2020-11-02       Impact factor: 13.801

10.  Aberrant DNA Methylation Is Associated with a Poor Outcome in Juvenile Myelomonocytic Leukemia.

Authors:  Hirotoshi Sakaguchi; Hideki Muramatsu; Yusuke Okuno; Hideki Makishima; Yinyan Xu; Yoko Furukawa-Hibi; Xinan Wang; Atsushi Narita; Kenichi Yoshida; Yuichi Shiraishi; Sayoko Doisaki; Nao Yoshida; Asahito Hama; Yoshiyuki Takahashi; Kiyofumi Yamada; Satoru Miyano; Seishi Ogawa; Jaroslaw P Maciejewski; Seiji Kojima
Journal:  PLoS One       Date:  2015-12-31       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.